662 related articles for article (PubMed ID: 32724470)
1. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, Screening, and Evaluation of Theranostic Molecular CPCR4-Based Probe Targeting CXCR4.
Yang T; Shi D; Lin Q; Shen H; Tan H; Liu Y; Shi H; Cheng D
Mol Pharm; 2024 May; 21(5):2415-2424. PubMed ID: 38606663
[TBL] [Abstract][Full Text] [Related]
3. Validation of [
Schottelius M; Ludescher M; Richter F; Kapp TG; Kessler H; Wester HJ
EJNMMI Res; 2019 Aug; 9(1):75. PubMed ID: 31410585
[TBL] [Abstract][Full Text] [Related]
4. [
Konrad M; Rinscheid A; Wienand G; Nittbaur B; Wester HJ; Janzen T; Lapa C; Pfob CH; Schottelius M
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3937-3948. PubMed ID: 37597009
[TBL] [Abstract][Full Text] [Related]
5. [
Schottelius M; Osl T; Poschenrieder A; Hoffmann F; Beykan S; Hänscheid H; Schirbel A; Buck AK; Kropf S; Schwaiger M; Keller U; Lassmann M; Wester HJ
Theranostics; 2017; 7(9):2350-2362. PubMed ID: 28744319
[No Abstract] [Full Text] [Related]
6. [
Lau J; Kwon D; Rousseau E; Zhang Z; Zeisler J; Uribe CF; Kuo HT; Zhang C; Lin KS; Bénard F
Mol Pharm; 2019 Nov; 16(11):4688-4695. PubMed ID: 31545614
[TBL] [Abstract][Full Text] [Related]
7. D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy.
Luyten K; Van Loy T; Cawthorne C; Deroose CM; Schols D; Bormans G; Cleeren F
Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683912
[TBL] [Abstract][Full Text] [Related]
8. Influence of corticosteroid treatment on CXCR4 expression in DLBCL.
Martin S; Viertl D; Janz A; Habringer S; Keller U; Schottelius M
EJNMMI Res; 2023 May; 13(1):40. PubMed ID: 37162652
[TBL] [Abstract][Full Text] [Related]
9. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent.
Gourni E; Demmer O; Schottelius M; D'Alessandria C; Schulz S; Dijkgraaf I; Schumacher U; Schwaiger M; Kessler H; Wester HJ
J Nucl Med; 2011 Nov; 52(11):1803-10. PubMed ID: 22045709
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of [(68)Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo - a comparison to [(68)Ga]pentixafor.
Poschenrieder A; Schottelius M; Schwaiger M; Wester HJ
EJNMMI Res; 2016 Dec; 6(1):70. PubMed ID: 27655427
[TBL] [Abstract][Full Text] [Related]
11. CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [
Jacobs SM; Wesseling P; de Keizer B; Tolboom N; Ververs FFT; Krijger GC; Westerman BA; Snijders TJ; Robe PA; van der Kolk AG
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):481-491. PubMed ID: 33550492
[TBL] [Abstract][Full Text] [Related]
12. The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity.
Poschenrieder A; Schottelius M; Schwaiger M; Kessler H; Wester HJ
EJNMMI Res; 2016 Dec; 6(1):36. PubMed ID: 27112767
[TBL] [Abstract][Full Text] [Related]
13. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
[TBL] [Abstract][Full Text] [Related]
14. First
Poschenrieder A; Osl T; Schottelius M; Hoffmann F; Wirtz M; Schwaiger M; Wester HJ
Tomography; 2016 Jun; 2(2):85-93. PubMed ID: 30042959
[TBL] [Abstract][Full Text] [Related]
15. [
Poschenrieder A; Schottelius M; Osl T; Schwaiger M; Wester HJ
EJNMMI Radiopharm Chem; 2017; 2(1):2. PubMed ID: 29527563
[TBL] [Abstract][Full Text] [Related]
16. Nuclear Medicine Application of Pentixafor/Pentixather Targeting CXCR4 for Imaging and Therapy in Related Disease.
Chen Z; Xue Q; Yao S
Mini Rev Med Chem; 2023; 23(7):787-803. PubMed ID: 36529918
[TBL] [Abstract][Full Text] [Related]
17. First-in-Human Experience of CXCR4-Directed Endoradiotherapy with 177Lu- and 90Y-Labeled Pentixather in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease.
Herrmann K; Schottelius M; Lapa C; Osl T; Poschenrieder A; Hänscheid H; Lückerath K; Schreder M; Bluemel C; Knott M; Keller U; Schirbel A; Samnick S; Lassmann M; Kropf S; Buck AK; Einsele H; Wester HJ; Knop S
J Nucl Med; 2016 Feb; 57(2):248-51. PubMed ID: 26564323
[TBL] [Abstract][Full Text] [Related]
18. High-Contrast CXCR4-Targeted
Kwon D; Lozada J; Zhang Z; Zeisler J; Poon R; Zhang C; Roxin Á; Lin KS; Perrin D; Benard F
Mol Pharm; 2021 Jan; 18(1):187-197. PubMed ID: 33253591
[TBL] [Abstract][Full Text] [Related]
19. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging.
Wester HJ; Keller U; Schottelius M; Beer A; Philipp-Abbrederis K; Hoffmann F; Šimeček J; Gerngross C; Lassmann M; Herrmann K; Pellegata N; Rudelius M; Kessler H; Schwaiger M
Theranostics; 2015; 5(6):618-30. PubMed ID: 25825601
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [
Günther T; Holzleitner N; Viering O; Beck R; Wienand G; Dierks A; Pfob CH; Bundschuh RA; Kircher M; Lapa C; Wester HJ
J Nucl Med; 2024 Jan; 65(1):33-39. PubMed ID: 37945383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
